To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
Initiator Pharma erhåller europeiskt patent för pudafensine vid kvinnlig sexuell dysfunktion, inklusive vulvodyni
Initiator Pharma A/S, ett emerging pharma bolag i klinisk fas som utvecklar innovativa läkemedel som riktar sig mot viktiga ouppfyllda medicinska behov inom centrala och perifera nervsystemet, meddelade idag att Europeiska patentverket (EPO) har beviljat bolagets europeiska patentansökan avseende pudafensine för behandling av kvinnlig sexuell dysfunktion (FSD).
Initiator Pharma granted European patent for pudafensine in Female Sexual Dysfunction, including vulvodynia
Initiator Pharma A/S, a clinical-stage biotech company developing innovative drugs targeting key unmet medical needs within the central and peripheral nervous system, today announced that the European Patent Office (EPO) has granted the company’s European patent application covering pudafensine for the treatment of Female Sexual Dysfunction (FSD).